Marc Belsky
Directeur Financier/CFO chez KEZAR LIFE SCIENCES, INC.
Fortune : 11 236 $ au 30/06/2024
Profil
Marc L.
Belsky is currently the Chief Financial Officer & Secretary at Kezar Life Sciences, Inc. He previously held positions as the Chief Accounting Officer & Vice President at Cell Genesys, Inc. from 2006 to 2009, the Chief Financial Officer at DataWave Systems, Inc. from 2001 to 2003, and the Chief Financial Officer & Senior Vice President at Five Prime Therapeutics, Inc. from 2009 to 2018.
Mr. Belsky also worked as an Auditor at Coopers & Lybrand LLP and as a Senior Vice President-Payment Products & Services at Michigan National Corp.
He served as the Vice President-Global Visa Commerce at Visa, Inc. from 2005 to 2006 and as the Chief Financial Officer at Active Aero Charter, Inc. He also held the position of Chief Financial Officer at Active Aero Group, Inc. from 2003 to 2005.
Mr. Belsky completed his undergraduate degree at Wayne State University (Michigan) and earned an MBA from the University of Michigan in 1979.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
KEZAR LIFE SCIENCES INC
0,03% | 01/04/2024 | 18 727 ( 0,03% ) | 11 236 $ | 30/06/2024 |
Postes actifs de Marc Belsky
| Sociétés | Poste | Début |
|---|---|---|
| KEZAR LIFE SCIENCES, INC. | Directeur Financier/CFO | 01/03/2018 |
Anciens postes connus de Marc Belsky
| Sociétés | Poste | Fin |
|---|---|---|
| FIVE PRIME THERAPEUTICS, INC. | Directeur Financier/CFO | 06/04/2018 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Comptroller/Controller/Auditor | 14/10/2009 |
| VISA, INC. | Corporate Officer/Principal | - |
Active Aero Group, Inc.
 Active Aero Group, Inc. AirlinesTransportation Active Aero Group, Inc provides air cargo, air charter and delivery services. The firm provides a transportation management system that works across various modes, including air freight, ground, and air charter. The company was founded in 1996 and is headquartered in Belleville, MI. | Directeur Financier/CFO | 01/01/2005 |
DataWave Systems, Inc.
 DataWave Systems, Inc. Miscellaneous Commercial ServicesCommercial Services DataWave Systems, Inc. develops prepaid and stored-value programs and merchandising solutions. It sells prepaid calling cards and point-of-sale activated prepaid cellular personal identification numbers on a wholesale basis to retail operators and other customers. The company was founded in 1994 and is headquartered in Richmond, Canada. | Directeur Financier/CFO | 01/01/2003 |
Formation de Marc Belsky
| University of Michigan | Masters Business Admin |
| Wayne State University (Michigan) | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| VISA, INC. | Commercial Services |
| KEZAR LIFE SCIENCES, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Active Aero Charter, Inc.
 Active Aero Charter, Inc. AirlinesTransportation Active Aero Charter, Inc. provides air cargo charter management services. Its online CharterNet service lets shipper's list freight for transport so carriers can bid for the business. The company is a subsidiary of Active Aero Group, Inc. Active Aero Charter was founded in 1996 and is headquartered in Belleville, MI. | Transportation |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
Active Aero Group, Inc.
Active Aero Group, Inc. AirlinesTransportation Active Aero Group, Inc provides air cargo, air charter and delivery services. The firm provides a transportation management system that works across various modes, including air freight, ground, and air charter. The company was founded in 1996 and is headquartered in Belleville, MI. | Transportation |
DataWave Systems, Inc.
DataWave Systems, Inc. Miscellaneous Commercial ServicesCommercial Services DataWave Systems, Inc. develops prepaid and stored-value programs and merchandising solutions. It sells prepaid calling cards and point-of-sale activated prepaid cellular personal identification numbers on a wholesale basis to retail operators and other customers. The company was founded in 1994 and is headquartered in Richmond, Canada. | Commercial Services |
| Coopers & Lybrand LLP | Commercial Services |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
| Michigan National Corp. | Finance |
